

## PierianDx unites with Cancer Genetics to enrich patient's care

15 March 2018 | News

PierianDx's Partnership with Cancer Genetics to Provide Comprehensive Precision Oncology Testing and Workflow Solution



PierianDx, the leading genomics technology company that enables precision medicine programs and molecular testing for healthcare organizations, announced partnership with Cancer Genetics, Inc. (CGI).

The partnership will provide a comprehensive precision oncology testing and workflow solution to enhance patient care.

CGI is a leader in enabling precision medicine for oncology through molecular markers and diagnostics.

The partnership combines CGI's Focus::NGS® offering, a suite of next generation sequencing (NGS) tests providing a comprehensive view of the patient genomic profile for both solid tumors and hematologic malignancies, with PierianDx's integrated NGS workflow and analysis solution: Clinical Genomics WorkSpace<sup>™</sup> (CGW), allowing for streamlined and accurate analysis, interpretation, and reporting.

Nagarajan, PierianDx founder and CEO, noted that the partnership will produce actionable clinical insights and reports for pathologists and oncologists utilizing both PierianDx interpretation services and CGW's KnowledgeSpace<sup>™</sup> which cultivates and curates billions of biomedical findings, expanding its intelligence with each use.

The KnowledgeSpace<sup>™</sup> includes curated variant classification guidelines by the Association of Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO), and the College of American Pathologists (CAP).

PierianDx's board-certified molecular pathologists and medical geneticists will further review cases to make assessments on medical meaningfulness of variants.

This information will include recommended therapeutic options, more aggressive or conservative disease monitoring, as well as recommended clinical trials, each of which offered in the appropriate clinical context.